# NCT04025879 (NCT04025879)

> A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04025879
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Nivolumab; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed; Placebo; Docetaxel
- Enrollment: 461
- Primary outcome: Event-Free Survival (EFS) by BICR

## Commentary we found

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04025879